----------------------------------------------
------------------------------------------------------------------
When trials are done in the name of brain cancer, it's clear that some will be noticed more than others. Very rarely have I ever tuned into a story of this nature to learn that the process is only going to take a day's time. This is a process that calls for attention to detail, so how much detail can be picked up on in such a limited amount of time, you may wonder? It's good to see that certain procedures are set in place, which is the case for the ETS2101 trial.
The Wall Street Journal posted an article in regards to the ETS2101 trial, which has entailed a number of patients affected with either primary or secondary brain cancer. Each of them was given a particular dose of ETS2101. This was done in order to see how well their bodies would take to it and if they would need larger or smaller amounts. The study will be done through 2014 as well, which means that organizations along the lines of Voices against Brain Cancer should bring their attention towards it.
For those who are unfamiliar with ETS2101, what exactly is it, you may wonder? The article said that this is a drug which has been utilized in the past in order to study trauma patients. However, instances of pharmacology have shown that this drug may actually prove useful in the way of cancer as well. With two ongoing studies being done - one for primary cancer patients and the other for secondary cancer patients - there has been a great deal of time that's been invested with this study.
With this procedure put into place, though, it's been said that patients have been given steadily higher doses over time until a tolerated level has been reached. Fifteen different patients have completed the studies and they were all given appropriate levels of the drug relative to body weight. The results have been positive, from what I have picked up on, as the tumors did not respond negatively to the drug. It's this level of success that, in my mind, can lead to further results down the road.
These studies require time in order for them to be truly effective, as just about anyone will be able to agree with. In my mind, brain cancer stands as one of the most serious conditions and, as a result, deserves all of the attention that it can get. This has been the case for the ETS2101 trial and it's good to see that it will continue on through 2014. During that time, I can only hope that even greater results will be seen, which can then parlay into the future.
The Wall Street Journal posted an article in regards to the ETS2101 trial, which has entailed a number of patients affected with either primary or secondary brain cancer. Each of them was given a particular dose of ETS2101. This was done in order to see how well their bodies would take to it and if they would need larger or smaller amounts. The study will be done through 2014 as well, which means that organizations along the lines of Voices against Brain Cancer should bring their attention towards it.
For those who are unfamiliar with ETS2101, what exactly is it, you may wonder? The article said that this is a drug which has been utilized in the past in order to study trauma patients. However, instances of pharmacology have shown that this drug may actually prove useful in the way of cancer as well. With two ongoing studies being done - one for primary cancer patients and the other for secondary cancer patients - there has been a great deal of time that's been invested with this study.
With this procedure put into place, though, it's been said that patients have been given steadily higher doses over time until a tolerated level has been reached. Fifteen different patients have completed the studies and they were all given appropriate levels of the drug relative to body weight. The results have been positive, from what I have picked up on, as the tumors did not respond negatively to the drug. It's this level of success that, in my mind, can lead to further results down the road.
These studies require time in order for them to be truly effective, as just about anyone will be able to agree with. In my mind, brain cancer stands as one of the most serious conditions and, as a result, deserves all of the attention that it can get. This has been the case for the ETS2101 trial and it's good to see that it will continue on through 2014. During that time, I can only hope that even greater results will be seen, which can then parlay into the future.
About the Author:
Visit Voices Against Brain Cancer if you are seeking some more information about glioblastoma and brain cancer awareness.. This article, Progression Of ETS2101 In Brain Cancer is available for free reprint.
0 comments:
Post a Comment